RxDoctor Payments Data

Kevin Orita, MD

Internal Medicine · Fresno, CANPI 1073076139

Payments from drug & device makers

$1,385in general payments, 2019–2025

Across 68 payments — averaging $20.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$240
  • Bayer$197
  • Lilly USA, LLC$178
  • Novo Nordisk$133
  • AstraZeneca$80
  • Exact Sciences$55
  • plus $503 from 17 others

What the payments were for

  • Food & beverage$1,36599%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,385 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$94,952
Medicare patients
255
Services billed
1,143

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin151$172,859
OzempicSemaglutide121$133,007
TrulicityDulaglutide66$90,525
JanuviaSitagliptin Phosphate72$77,919
EliquisApixaban69$60,032
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$46,861
XifaxanRifaximin13$40,288
LinzessLinaclotide52$37,244
RybelsusSemaglutide23$31,819
MounjaroTirzepatide28$28,920
WegovySemaglutide17$24,158
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog59$21,239
FarxigaDapagliflozin Propanediol15$16,306
MyrbetriqMirabegron19$15,920
TradjentaLinagliptin12$14,331

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$133$188,984161 claims
Boehringer IngelheimJardiance, Tradjenta$32$187,190163 claims
Lilly USA, LLCTrulicity, Mounjaro$178$119,44594 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$240$61,72592 claims
PfizerEliquis$43$60,03269 claims
AbbVieLinzess$23$37,24452 claims
AstraZenecaFarxiga, Pulmicort Flexhaler$80$20,52232 claims
NovartisEntresto$17$7,90812 claims
BayerKerendia$197$7,18812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →